Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

For each subject, the trial is expected to take 14.5 months: 2.5 months for screening and subject treatment and a further 12 months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/...ense company developing medical countermeasures ag...oday the presentation of new data from the Company...lized recombinant Protective Antigen (rPA) based a...fter 16 months at various temperatures up to and i...
(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -...se company developing medical countermeasures agai...ay that the Company is presenting results of a stu...4; in an inhalation anthrax model in the New Zeala...ed during an oral session at the HHS Public Health...
(Date:12/4/2009)... , MORRISTOWN, N.J., Dec. 4 /PRNewswire-FirstCa..., a leading global specialty pharmaceutical compan...oratories, Inc.-Florida, filed an Abbreviated New ...g Administration seeking approval to market its 8m...atent owned by Takeda Pharmaceutical Company Limit...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Chiropractors Focus on Patients Best Interest 54503 1Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 54501 1Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 54501 2Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 54501 3Ophthalmology Pioneer Dr Jeffrey P Gilbard Dies 54498 1Ophthalmology Pioneer Dr Jeffrey P Gilbard Dies 54498 2Ophthalmology Pioneer Dr Jeffrey P Gilbard Dies 54498 3
...nhua-PRNewswire-FirstCall/,-- Pharmaceutical compa...Phase II trial for Aridol in subjects with Chronic...ry disease,affecting over 30 million people worldw...D patients at 12,centres in Australia. The primary...ts that were positive to an Aridol challenge,test ...
...of key product in,AM-Pharma,s pipeline , BUNNIK, T...e,biopharmaceutical company developing novel thera...ses, today announced positive,results in patients ...re a subgroup of a Phase IIa trial with Alkaline P...earance, a marker for renal function,improved by ...
Other Medicine Technology:Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial,with Alkaline Phosphatase in Acute Renal Failure 2AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial,with Alkaline Phosphatase in Acute Renal Failure 3
(Date:12/4/2009)... the H1N1 virus will come back during winter isn,t...ealthDay News) -- The number of states reporting w...this week -- to 25 from a high of 48 just two week...anwhile, the supply of H1N1 swine flu vaccine cont... of the U.S. Centers for Disease Control and Preve...
(Date:12/4/2009)...s more smoke inhaled through hookah, research show... Water pipes are no safer than cigarettes for smok...nd that people who smoke tobacco with a water pipe...hem at risk for heart disease and nicotine addicti... to 50, who smoked tobacco using a water pipe and ...
(Date:12/4/2009)...tudy found they spurred blood vessel growth after ...ay News) -- Adult stem cells appear to help repair...phase 1 study of 53 patients found that stem cells... blood vessels in heart tissue damaged by heart at...ections within 10 days of having a heart attack. D...
(Date:12/4/2009)... , MADISON, Wis., Dec. 4 /PRNewswire-FirstCall...fall, the Wisconsin Department of Health Services ... quickly than ever before. Join Sonic Foundry, In... for rich media webcasting and knowledge managemen... Wisconsin Department of Health Services, will sha...
(Date:12/4/2009)... , BOULDER, Colo., Dec. 4 ... ON LOVE ,, Kathryn Budig, a prominent yoga tea... to healing--with a viewing of Twilight,s New Moon...al.com: ,, http://www.elephantjournal.com/2009...urnal.com: TASHI KING AND BREAST CANCER ,, ele...
Breaking Medicine News(10 mins):Health News:Swine Flu Continues to Wane 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...lthcare, a division of the $150-billion General El...nce with Manipal Health Systems (MHS) to conduct c...dia. The trials will be conducted at the Bang...spital for $7 million and invested another $1.5-2 ...
...ds of jobs will be terminated and hospital wards w...Hospital is struggling with financial pressures//....sion made by primary care center to refer fewer pa... Unison’s Geoff Reason, describing the news as ...
...istopher Landrigan, from Harvard University, a spe...red a report on the repercussions of lack of sleep... been deputed by the health board to lend his obse...e reaching a stalemate. Dr Stephen Child, th...
...ine, to prevent the attack of the deadly bird flu ...es, after the initial trial reports announce it sa...cine, developed by Melbourne pharmaceutical manufa... bird flu and is the only one of its kind, being d...
...l misconceptions have prevented many people espec...ng eggs//. The July issue of the Harvard Heart Let...the egg. Fact: Eggs are a good source of nutr...serving memory, and lutein and zeaxanthin, which m...
...er Army Major questioned a particular research, wh...sed cancer rates among those who took part in Brit...their exposure to radiation//. According to th...to their exposure to radiation. However Vetera...
Other Medicine News:Health News:GE Healthcare to Conduct Clinical Trials in India 2
...fectively delivers clinically proven aminophylline...duction. Topical fat reduction with the aminophyll...on in fat and an increase in the firmness of the t...o the skin where it causes the body fat cells to s...
...ur is a non-invasive massage machine for skin, sca...m. Extraordinary results are achieved with our fam... vertical and parallel forces to produce effective...p tissue mobilization, kneading and compression, s...
Starvac SP2 Vacuum Cellulite Massage Therapy
Ritter 204 Manual Exam Table
Medicine Products: